Baidu
map

研究进展,对抗H7N9冬日来袭!

2014-01-21 MedSci MedSci原创

18日,上海浦东新区人民医院的张晓东医生因H7N9禽流感而不幸去世。H7N9又一次活跃到大家眼前。H7N9在这个冬季卷土重来。中国疾控中心副主任冯子健告诉新京报记者,从去年3月底(我国报告全球首例人感染H7N9禽流感病例)至1月19日晚12时,全国累计报告人感染H7N9确诊病例已超过200例。从去年11月,全国各地相继爆出H7N9感染病例,但主要分布在我国东南部地区,如浙江、上海、广东等省份。目前

18日,上海浦东新区人民医院的张晓东医生因H7N9禽流感而不幸去世。H7N9又一次活跃到大家眼前。

H7N9在这个冬季卷土重来。中国疾控中心副主任冯子健表示,从去年3月底(我国报告全球首例人感染H7N9禽流感病例)至1月19日晚12时,全国累计报告人感染H7N9确诊病例已超过200例。

从去年11月,全国各地相继爆出H7N9感染病例,但主要分布在我国东南部地区,如浙江、上海、广东等省份。目前H7N9疫情在人间仍处于散发状态。


以下 ,小编将近期各大杂志期刊有关于H7N9研究的最新成果罗列出,供各位参考学习!

1、来源和传播:

2、变异和耐药:


3、疫苗和进展


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=7096, encodeId=6d81e09633, content=新型疫苗,或达菲是否有效?中药能不能可以尝试?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=boer, createdTime=Sat Jan 25 21:39:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7095, encodeId=c2f9e09541, content=这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=finning, createdTime=Sat Jan 25 21:38:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7065, encodeId=2c77e065e9, content=预防是第一位的!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.40.34, createdTime=Fri Jan 24 00:03:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380406, encodeId=7478138040650, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477446, encodeId=c49814e7446aa, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
    2014-01-25 boer

    新型疫苗,或达菲是否有效?中药能不能可以尝试?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=7096, encodeId=6d81e09633, content=新型疫苗,或达菲是否有效?中药能不能可以尝试?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=boer, createdTime=Sat Jan 25 21:39:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7095, encodeId=c2f9e09541, content=这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=finning, createdTime=Sat Jan 25 21:38:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7065, encodeId=2c77e065e9, content=预防是第一位的!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.40.34, createdTime=Fri Jan 24 00:03:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380406, encodeId=7478138040650, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477446, encodeId=c49814e7446aa, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
    2014-01-25 finning

    这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=7096, encodeId=6d81e09633, content=新型疫苗,或达菲是否有效?中药能不能可以尝试?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=boer, createdTime=Sat Jan 25 21:39:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7095, encodeId=c2f9e09541, content=这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=finning, createdTime=Sat Jan 25 21:38:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7065, encodeId=2c77e065e9, content=预防是第一位的!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.40.34, createdTime=Fri Jan 24 00:03:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380406, encodeId=7478138040650, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477446, encodeId=c49814e7446aa, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
    2014-01-24 60.55.40.34

    预防是第一位的!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=7096, encodeId=6d81e09633, content=新型疫苗,或达菲是否有效?中药能不能可以尝试?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=boer, createdTime=Sat Jan 25 21:39:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7095, encodeId=c2f9e09541, content=这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=finning, createdTime=Sat Jan 25 21:38:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7065, encodeId=2c77e065e9, content=预防是第一位的!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.40.34, createdTime=Fri Jan 24 00:03:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380406, encodeId=7478138040650, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477446, encodeId=c49814e7446aa, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=7096, encodeId=6d81e09633, content=新型疫苗,或达菲是否有效?中药能不能可以尝试?, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=boer, createdTime=Sat Jan 25 21:39:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7095, encodeId=c2f9e09541, content=这次传播速度并不快,关键还要看预防,应该不会引发大规模的传播。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=finning, createdTime=Sat Jan 25 21:38:00 CST 2014, time=2014-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7065, encodeId=2c77e065e9, content=预防是第一位的!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=60.55.40.34, createdTime=Fri Jan 24 00:03:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380406, encodeId=7478138040650, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477446, encodeId=c49814e7446aa, content=<a href='/topic/show?id=9f7d8411fc' target=_blank style='color:#2F92EE;'>#H7N9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8411, encryptionId=9f7d8411fc, topicName=H7N9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1f27379114, createdName=ms117281293605716, createdTime=Thu Jan 23 07:46:00 CST 2014, time=2014-01-23, status=1, ipAttribution=)]

相关资讯

ERAIT:美研究发现可有效对抗H7N9的天然抗生素

中国科学院病原微生物与免疫学重点实验室对H7N9禽流感病毒进行的基因溯源研究显示:由鸽子或者雀鸟等禽类引起H7N9流感病毒在中国已经超过130人感染,导致43人死亡。病毒基因来自东亚地区野鸟和中国上海、浙江、江苏鸡群的基因重配,病毒自身基因变异可能是H7N9型禽流感病毒感染人并导致高死亡率的原因。 针对该种变异的药物治疗日前在美国堪萨斯州立大学取得一定进展,该大学的Juergen Richt

H7N9在冬季卷土重来 累计突破200人

新京报讯 H7N9在冬季卷土重来。昨晚,中国疾控中心副主任冯子健告诉新京报记者,从去年3月底(我国报告全球首例人感染H7N9禽流感病例)至1月19日晚12时,全国累计报告人感染H7N9确诊病例已超过200例。去年12月至今,H7N9又处于比较活跃的状态,“发病高峰再次出现。”冯子健说,目前H7N9疫情在人间仍处于散发状态,但主要分布在我国东南部地区,如浙江、上海、广东等省份。中疾控:H7N9未现重

Nat Commun:抗药性H7N9流感病毒有高度传播性

新出现的H7N9流感病毒的一个突变能使其对惟一一类对该病毒有活性的药物产生抵抗力,而不会影响其在动物中传播的能力。发表在本期Nature Communications上一篇研究论文中的这一发现表明,与季节性流感不同的是,抗药性H7N9病毒能够与非抗药性H7N9病毒同样高效地在动物中复制。 Nicole Bouvier及同事对从中国一位患者身上分离出的突变的H7N9病毒进行了分析,以了解它对药物的

CMI:H7N9禽流感患者免疫反应和临床结局相关影响因素

进入秋冬季后,H7N9病毒又卷土重来。浙江,广东相继报告多例人感染H7N9禽流感病例。关于这一新病毒引起的机体的免疫反应和该疾病的临床特征还未知。来自上海市公共卫生临床中心的研究人员对该中心收治的18例病人的临床特征和机体的免疫反应进行研究分析。结果认为,病人体内的高病毒载量和强烈的细胞因子风暴是人感染H7N9禽流感重要的发病机制。该研究发表在 2013年12月18日的《临床微生物和感染》(cli

卫计委公布2013年中国卫生计生十大新闻

7日上午,国家卫生计生委举行新闻发布会。国家卫生和计划生育委员会宣传司司长、新闻发言人毛群安介绍了2013年中国卫生计生十大新闻。 这十大新闻是:国家卫生和计划生育委员会成立。党中央国务院对深化医改进行全面部署。坚持计划生育基本国策,启动实施单独两孩政策。妥善应对H7N9疫情等突发公共卫生事件。进一步扩大卫生援外合作,中国援外医疗队派遣50周年系列纪念活动举办。深入开展党

PNAS:对H7N9的细胞介导免疫具有种族差异

日前,来自澳大利亚墨尔本大学等机构的科学家发现,由于参与细胞介导免疫应答的一个蛋白质复合体的遗传差异,人们对 2013 年 2 月出现的 H7N9 流感病毒启动一种细胞介导免疫的能力可能不同。【原文下载】 人类此前没有遇到过 H7N9 病毒,因此缺乏抵抗这种病毒的保护性抗体。动物和人类研究显示,在缺乏抵抗一种新流感毒株的保护性抗体的情况下,此前产生的抵抗其他流感毒株的

Baidu
map
Baidu
map
Baidu
map